SLC5A2 and metabolic dysfunction-associated steatotic liver disease: This was inspired by the positive effects of SGLT2 inhibitors in patients with metabolic and inflammatory pathologies, such as DM2 [80] and associated heart failure [81], diabetic cardiomyopathy and nephropathy [80], decrease in cognitive functions, non-alcoholic fatty liver disease (NAFLD) [82], hypertension [83], and other pathologies [11].